Worldwide, the percentage of the population affected with haemophilia is estimated at 1 per 10,0002 , which, under EU guidance, classifies it as a rare disease (defined as less than 5 per 10,000). Through its Public Health and Research Programmes, the EU has identified rare diseases as an EU health policy priority because, with such low number of patients, it has been agreed by Member States that special efforts, combined and cross-national, are needed to address them. The most accurate figures on the number of haemophilia patients in the EU can be drawn.